![Beam Therapeutics](https://www.adcreviews.com/wp-content/uploads/2022/08/Beam-Therapeutics-300x157.jpeg)
IND application for BEAM-201 suspended by FDA
On August 1, 2022, base editing company Beam Therapeutics announced that its IND application for BEAM-201 was suspended by the FDA. The FDA will provide
On August 1, 2022, base editing company Beam Therapeutics announced that its IND application for BEAM-201 was suspended by the FDA. The FDA will provide